drugset / Trial / NCT02220868

Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study

NCT02220868

Phase 4 Completed 10 enrolled Saint Michael's Medical Center
NaSingle-groupOpen-labelTreatment

Summary

The protocol will study the safety and efficacy of using sofosbuvir and ribavirin for the treatment of hepatitis c in patients taking stribild.

Timeline

Start
2014-07
Primary completion
2015-08
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ribavirin Small molecule 1000 mg
Subject Ribavirin Small molecule 1200 mg
Subject Sofosbuvir Small molecule 400 mg
Background Stribild Other / unclassified